Mylan sues to block Ranbaxy's Lipitor exclusivity; Genzyme can't meet Thyrogen demand;

@FiercePharma:  Pfizer exec outlines spin-off strategy. News | Follow @FiercePharma

> Citing manufacturing violations at Ranbaxy Laboratories plants, Mylan has sued the FDA in an effort to block the Indian company's exclusive rights to sell a generic version of Pfizer's cholesterol pill Lipitor, the world's best-selling medicine. News

> Genzyme will be unable to meet demand for its thyroid drug Thyrogen until July 2011 because of a manufacturing issue. Story

> Novartis expects growth in China to recover after business restructuring in the country slowed the Swiss drug giant's sales here last year, Chief Executive Joe Jimenez said. Report

> The U.S. government and Johnson & Johnson each filed patent-infringement lawsuits against Teva Pharmaceutical Industries to block sales of a generic version of the HIV medicine Prezista. Item

> Pharmacy benefits provider Medco Health Solutions said it received a subpoena from U.S. securities regulators for documents related to an ongoing probe of California's pension fund for public employees. News

> A unique Michigan law bars the state from suing Merck to recover millions of dollars spent on Vioxx, an arthritis drug pulled from the market because of health risks, a court said. Item

> Eli Lilly, which faces plunging sales due to competition and lapsing patents, will not merge with another peer to ride out any rough times ahead, CEO John Lechleiter said once again. Article

> Sanofi-Aventis said it had received European Commission authorization to market its prostate cancer drug Jevtana. Report

> Merck and Teva Pharmaceutical Industries said a European advisory committee gave a positive recommendation for their birth control tablet for women. Story

> Biotechnology, medical technology and pharmaceutical companies are crucial to New Jersey's economy, supporting more than $7.5 billion in tax revenue, leaders of state organizations and lobbying groups said. News

Biotech News

@FierceBiotech: Takeda looks to Deborah Dunsire to guide oncology work. Report | Follow @FierceBiotech 

> Roche tees up new app on promising Ph2 cancer drug. Story

> Venture backers inject $25M into Synageva's rare disease platform. News

> Big Pharma urged to follow biotech's lead on execs' incentive deals. Report

> Struggling XenoPort shelves GERD program after Ph2b failure. Article 

> Quest Diagnostics snags Celera in $344M buyout. Item 

Biotech IT News

> FDA hard-to-search files hold drug safety clues. Report 

> Oracle targets subject recruitment at hospitals. Article 

> Medidata financials strong despite NCI contract termination. Item 

> Survey: Data tracking complexity on the rise. News

> CRO device automates cardiac trial monitoring. Story 

> MS Sharepoint portals get digital signatures. Report 

Medical Device News

> Oxford Finance, GE Capital give $20M senior credit facility to NeoVista. Story 

> Medtronic CFO: No shift away from GPOs. Article 

> BridgePoint taps Harrington as CEO. News 

> Stryker CEO sees big bonus in 2010. Report

> Given Imaging gets win in patent fight. Item 

> Zimmer scores government contract. News 

> CardioNexus gets FDA ok for cardiac ultrasound system. Story 

And Finally... Children as young as 4 are being given Ritalin-style medication for behavioural problems in breach of NHS guidelines, the Guardian reports. Report

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.